key: cord-0917308-1elq61nk
authors: Pitcovski, Jacob; Gruzdev, Nady; Abzach, Anna; Katz, Chen; Ben-Adiva, Ran; Schwartz, Michal Brand; Yadid, Itamar; Haviv, Hadar; Rapoport, Irena; Bloch, Itai; Shadmon, Roy; Eitan, Zohar; Eliahu, Dalia; Hilel, Talia; Laster, Morris; Tal, Sigal Kremer; Tennenbaum, Tamara Byk; Shahar, Ehud
title: Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine
date: 2021-06-09
journal: bioRxiv
DOI: 10.1101/2021.06.09.447656
sha: b6857e11616e7a8e4953e70ad1eebeefafcc411f
doc_id: 917308
cord_uid: 1elq61nk

The rapid spread of the COVID-19 pandemic, with its devastating medical and economic impacts, triggered an unprecedented race toward development of effective vaccines. The commercialized vaccines are parenterally administered, which poses logistic challenges, while adequate protection at the mucosal sites of virus entry is questionable. Furthermore, essentially all vaccine candidates target the viral spike (S) protein, a surface protein that undergoes significant antigenic drift. This work aimed to develop an oral multi-antigen SARS-CoV-2 vaccine comprised of the receptor binding domain (RBD) of the viral S protein, two domains of the viral nucleocapsid protein (N), and heat-labile enterotoxin B (LTB), a potent mucosal adjuvant. The humoral, mucosal and cell-mediated immune responses of both a three-dose vaccination schedule and a heterologous subcutaneous prime and oral booster regimen were assessed in mice and rats, respectively. Mice receiving the oral vaccine compared to control mice showed significantly enhanced post-dose-3 virus-neutralizing antibody, anti-S IgG and IgA production and N-protein-stimulated IFN-γ and IL-2 secretion by T cells. When administered as a booster to rats following parenteral priming with the viral S1 protein, the oral vaccine elicited markedly higher neutralizing antibody titres than did oral placebo booster. A single oral booster following two subcutaneous priming doses elicited serum IgG and mucosal IgA levels similar to those raised by three subcutaneous doses. In conclusion, the oral LTB-adjuvanted multi-epitope SARS-CoV-2 vaccine triggered versatile humoral, cellular and mucosal immune responses, which are likely to provide protection, while also minimizing technical hurdles presently limiting global vaccination, whether by priming or booster programs. Highlights MigVax-101 is a multi-epitope oral vaccine for SARS-CoV-2. MigVax-101 elicits neutralizing IgG and IgA production and cellular responses in mice MigVax-101 serves as an effective booster in rats to a parenteral anti-S1 vaccine.

Plasmids were electro-transformed into E. coli C41 (Lucigen) and plated on LB-agar 128 supplemented with 50μg/mL kanamycin and 1% glucose. Colonies carrying the plasmid were 129 grown in a shaker incubator in LB medium (10 g/l bactotryptone, 5g/L yeast extract) 130 supplemented with 1% glucose, 100 µg/mL kanamycin, at starters/flask volume ratio: 1/100 and 131 then in 2×YT medium (16 g/l bactotryptone, 10 g/l yeast extract, 5 g/L NaCl), containing 100 132 µg/mL kanamycin, at 37 °C at 250 rpm, A 600 reached 0.6. The growth temperature was lowered 8 to 25°C, and after 20 min, 0.4 mM IPTG was added. Cells were further grown for 16 hours at 134 25°C, collected (4,500 x g, 20 min, 4 °C) and then lysed by sonication (45 A, 5 sec on/10 sec off, 135 3 repeats with 10 min rest between intervals, on ice) with lysis buffer (50 mM phosphate buffer 136 pH 7.2, 150 mM NaCl, 0.1% Tween 20 (latter for LTB-NC and LTB-NN) 1 tablet of protease 137 inhibitor per 500 ml culture)). The lysate was clarified by centrifugation (2 cycles of 15,000 x g, 138 20 min, 4 °C). (Fig. 2a) . On 49 dpi, mice administered oHD-LTB 292 exhibited anti-S1 IgG levels (p=0.0253) that were significantly higher than those measured on 26 293 dpi, whereas levels in the other two oral vaccination groups showed smaller increments in IgG 294 levels (Fig. 2b) . No change in IgG levels was noted after the third gavage vaccination (Fig. 2b) .

Three oral vaccinations with oHD and oHD-LTB induced a significant rise in secretory anti-S1 296 IgA levels as compared to the negative PBS-treated control (Fig. 2c, 14 .6-fold, p<0.001 and 9.3-297 fold, p<0.05, respectively).

Mice immunization with oHD-LTB and oHD provided for significantly higher neutralization 299 than both the gHD-LTB and the control groups (Fig. 3) . were observed following N induction (Fig. 4a ). In addition, IFN-γ-secreting T-cell counts were 304 significantly higher among splenocytes from oHD-LTB mice as compared to splenocytes from all other test groups (Fig. 4b, p<0 .001). Following splenocyte stimulation with N protein, IL-2 306 levels secreted by cells collected from oHD-LTB mice were significantly higher (p<0.01 or 307 0.001) than those secreted by splenocytes of all other treatment groups (Fig. 4c) . No significant 308 intergroup differences were noted with regard to secreted levels of IFNγ, or the Th-2 related 309 cytokines IL-10 and IL-4. Following S1 stimulation, splenocytes derived from oHD-LTB and 310 oLD-LTB mice secreted significantly higher IFNγ levels as compared to the gHD-LTB 311 splenocytes (p<0.05) (Fig. 4d) .

Oral boosting after S1 injection increases production of neutralizing antibodies 313 Having established that the oral vaccine is immunogenic in mice, we wished to evaluate the 314 ability of the oral vaccine to act as a booster vaccine in rats that had been immunized with a 315 model systemic vaccine (Fig. 1 ) Antibody titres were not further elevated following a second 316 oral booster (Fig. 5a) . Administration of a MigVax-101 oral boost after one or two injections of 317 S1 did not significantly increase anti-S1 IgG as compared to placebo (Fig. 5a) . Anti-S1 IgA 318 levels measured in BALF were increased after priming with one S1 injection and boosting with 319 one oral MigVax-101 dose as compared to rats receiving a single oral placebo boost (Fig. 5b) . 320 Furthermore, two subcutaneous S1 doses, followed by one oral MigVax-101 boost elicited IgA 321 levels at least as high as those obtained following three injections (Fig. 5b) . Similarly, two oral 322 MigVax-101 doses after two injections were associated with non-significant increase in anti-S1 323 IgA levels as compared to two injections followed by two oral placebo administrations (Fig. 5b) .

The levels of neutralizing antibodies were elevated in the serum of rats vaccinated with injected 325 S1 protein following a heterologous oral boost with MigVax-101.

For all vaccination 326 schedules, rats receiving the oral booster showed significantly higher neutralizing antibody titres 327 than those treated with an oral placebo booster (Fig. 6) . A double subcutaneous priming regimen, 328 followed by a single oral MigVax-101 booster, or a third subcutaneous S1 injection booster, 329 yielded similar neutralizing antibody titres 14 days after the boost in the oral and injectable boosts groups. Both were significantly higher than two injections alone followed by placebo at 331 this time point. (Fig. 6) . 

In another aspect, data variability may have been, at least partially, attributed to ununiformed 353 time of exposure of the administered vaccine at the rodent's oral cavity.

oHD-LTB was associated with more intense Th1 responses to S or N antigens, as shown by 356 higher IFN-γ-secreting T-cell counts and cytokine secretion, as compared to other test groups.

In addition, No shifts in the CD8 to CD4 population ratio were noted in any treatment group (as 358 determined by FACS; data not shown).

When administered as a booster to rats that had been subcutaneously immunized with viral S1 360 protein, MigVax-101 markedly enhanced neutralizing antibody levels, with the effect of a single 361 oral booster following two injected S1 doses corresponding to that following three injected oral MigVax-101 was administered once or twice at a 14-day interval. Control rats received one 641 or two injections of S1, followed by one or two oral doses of PBS or a third injected dose of S1. or twice, at a 14-day interval, with adjuvanted S1 subunit. Two weeks after the last priming dose, 650 oral MigVax-101 was administered once or twice, at 14-day interval. Control rats received one 651 or two injections of S1, followed by one or two oral doses of PBS or a third injected dose of S1. 

WHO Coronavirus disease (COVID-19) situation report

WHO Draft landscape and tracker of COVID-19 candidate vaccines Published

Intranasal and oral vaccination with protein-based 452 antigens: advantages, challenges and formulation strategies

SARS-CoV-2-530 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Broad and strong memory 533

CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following 534 COVID-19

Vaccine and adjuvant activity of 536 recombinant subunit B of E. coli enterotoxin produced in yeast

A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-539

Mediated Cell Entry and Its Inhibition

Antibody responses to 541 SARS-CoV-2 in patients with COVID-19

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice 544 and macaques

The Challenges of Vaccine Development against Betacoronaviruses

Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector

SARS CoV subunit 550 vaccine: antibody-mediated neutralisation and enhancement

Anti-spike IgG causes severe acute

Clinical progression and 556 viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective 557 study

RBD219-N1) formulated with aluminum 560 hydroxide induces protective immunity and reduces immune enhancement

The SARS-CoV nucleocapsid protein: a protein with multifarious 563 activities

A prime-boost 565 vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS 566 coronavirus

Dendritic cell targeted chitosan 568 nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein

Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations 572 with Age and Disease Severity

Clinical and immunological 574 assessment of asymptomatic SARS-CoV-2 infections

Robust 576 T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

of Novel Coronavirus-Infected Pneumonia